Description

Clonazepam Tablets

Clonazepam Tablets USP / BP / IP (0.5 mg / 1.0 mg / 2.0 mg)

High-Potency Nitro-Benzodiazepine Anticonvulsant & Myoclonic Stabilizer

Healthy Life Pharma Private Limited, together with our specialized global export and marketing division Healthy Inc, is an authorized manufacturer, CDMO partner, and wholesale exporter of advanced neurological, psychiatric, and emergency anti-epileptic therapeutics. We manufacture ultra-high-purity, kinetically stable Clonazepam Tablets inside our state-of-the-art, WHO–GMP certified, high-containment psychotropic production facilities.

As a primary clinical choice for both long-term seizure management and acute panic suppression, this formulation serves as a high-velocity strategic export to neurology networks, public hospital emergency infrastructures, national health ministry tenders, and international digital B2B pharmaceutical marketplaces across the CIS region, Africa, LATAM, and South-East Asia.

Product Overview

This formulation operates as a “Long-Acting Synaptic Inhibition Amplifier.” It ensures patient safety and prevents chaotic electrical storms in the brain by reinforcing the central nervous system’s internal neural gating systems.

• Mechanism 1 (High-Affinity Benzodiazepine Binding): Clonazepam possesses a highly potent chlorinated nitro-benzodiazepine structure. It physically binds with extreme affinity to allosteric target sites on $\text{GABA}_{\text{A}}$ receptor complexes heavily distributed across the cerebral cortex and cerebellum.

• Mechanism 2 (Post-Synaptic Hyperpolarization): This binding chemically accelerates the opening frequency of linked chloride channels in response to endogenous gamma-aminobutyric acid ($\text{GABA}$). The massive influx of negative chloride ions hyperpolarizes the post-synaptic neuron.

• Mechanism 3 (Seizure Focus Suppression): By raising the electrical firing threshold of neural networks, it physically limits the spread of hyper-synchronous electrical discharges. This mechanism quickly suppresses active seizure foci, suppresses abnormal myoclonic twitches, and dampens hyper-excitable panic pathways within the amygdala.

Product Composition & Available Strengths

We supply Clonazepam across the complete, internationally standardized therapeutic spectrum to facilitate precise titration for both pediatric epilepsy and high-potency adult neurological control.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the central nervous system / Psychotropics / Benzodiazepines)

• CAS Number: 1622-61-3 (Clonazepam)

• Dosage Form: Oral Solid Tablet (Cross-scored to ensure safe, exact fractioning for personalized low-dose pediatric regimens)

• Packaging Configurations: 10 / 14 / 15 Tablets per Blister Strip packed exclusively in premium high-barrier Alu-Alu (Cold-Form Foil) or light-resistant deep-amber PVC/PVDC matrix strips. Our tropicalized packaging completely isolates the active chemical core from environmental humidity and UV transit, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

Psychotropic Manufacturing Governance & Quality Control

• Dedicated Schedule X Environmental Isolation: Clonazepam operates at profound physiological micro-doses. To satisfy rigid international B2B regulatory audits, our tableting lines run inside Dedicated, Negative-Pressure Cleanroom Suites. These blocks utilize independent, HEPA-filtered HVAC infrastructures to guarantee absolute zero active chemical cross-contamination.

• Geometric Multi-Stage Blending Precision: Because active Clonazepam constitutes a tiny fraction of the total tablet core mass, we deploy Automated Multi-Stage Geometric Solid Blending Suites with Online Weight Variation Checkers, physically ensuring absolute chemical uniformity down to the microgram.

• Validated Release and Disintegration Kinetics: Every export production batch physically undergoes Automated In-Vitro Dissolution Profiling, chemically validating that our generic formulations achieve quick gastric disintegration and precise bioequivalence to match global innovator references (such as Rivotril / Klonopin).

Primary Indications

• Neurology & Epilepsy: Frontline treatment of Lennox-Gastaut Syndrome, akinetic and myoclonic seizures, infantile spasms (West Syndrome), and absence seizures refractory to standard succinimides.

• Psychiatry: Long-term management and stabilization of acute Panic Disorder, with or without Agoraphobia, and adjuvant stabilization of acute manic states in bipolar disorders.

Usage Instructions

• Administration Matrix: Swallow the tablet physically whole with a glass of water. It can be taken consistently either with or without food.

• The Tolerance Threshold Warning: Clonazepam exhibits an extended intermediate elimination half-life (30 to 40 hours), which provides highly stable steady-state plasma concentrations. However, chronic unmonitored usage can chemically induce physiological tolerance and habituation.

• The Tapered Withdrawal Protocol: Advise clinical and pharmacy networks that patients must NEVER halt Clonazepam abruptly. Sudden withdrawal can destabilize central GABA networks, physically triggering an intensive rebound phenomenon characterized by severe status epilepticus seizures, extreme psychosis, or muscle tremors. Doses must be tapered down progressively under direct specialist observation.

• Central Depressant Interaction Management: Patients must strictly avoid alcohol, barbiturates, or narcotic analgesics. Co-administration chemically multiplies central nervous system depression, physically risking severe respiratory depression, profound coma, or fatal toxicity.

Safety Warning: POTENT LONG-ACTING SCHEDULED ANTICONVULSANT. Controlled Drug Class — For Neurology and Psychiatry Specialist Supervision Only. Abrupt Cessation Danger: Never discontinue therapy abruptly; rapid withdrawal can physically trigger life-threatening, continuous Status Epilepticus Seizures. Sedation Safety Note: Extended half-life can induce long-acting daytime drowsiness or motor impairment; advise patients against operating automated industrial machinery or driving. Contraindications: Absolute contraindications in patients presenting with severe chronic respiratory insufficiency, severe hepatic impairment (risk of precipitating encephalopathy), sleep apnea, narrow-angle glaucoma, or known hypersensitivity to nitro-benzodiazepine derivatives.

Controlled Global Supply Chain & CDMO Licensing

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and high-volume private label export supply for the entire Clonazepam dosage spectrum. Operating under strict narcotics and controlled-substances authority clearances, we handle all mandatory international cross-border documentation (Official Ministry of Health Psychotropic Import Permits, Central Bureau of Narcotics – CBN Export Licenses, WHO-GMP Certificate, COPP, COA, and Complete CTD Format Dossier sets) for seamless import entry.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Regulatory Helpline: +91 7710003340

• Controlled Substances Registry Email: info@healthyinc.co.in